Sunday, May 26, 2019
CHA Medical Group to Open Fertility Hospital in Taiwan
Listing on Singapore Stock Market Planned
CHA Medical Group to Open Fertility Hospital in Taiwan
  • By Michael Herh
  • May 29, 2018, 11:18
Share articles

CHA Healthcare, the investment arm of the CHA Medical Group's hospital business, recently decided to invest 9 billion won (US$8.1 million) to build a fertility center in Taipei, Taiwan.
CHA Healthcare, the investment arm of the CHA Medical Group's hospital business, recently decided to invest 9 billion won (US$8.1 million) to build a fertility center in Taipei, Taiwan.

The CHA Medical Group, renowned for the treatment of infertility, will enter the hospital business in Taiwan. The CHA Medical Group has a plan to create synergies by investing its capabilities for infertility treatment and hospital management in Taiwan while, at the same time, seeking to secure Asian assets for being listed on the stock market in Singapore.

According to the investment banking industry on May 28, CHA Healthcare, a subsidiary of the CHA Medical Group's hospital investment business, recently decided to invest 9 billion won to build a fertility center in Taipei, Taiwan. The hospital will break ground for the hospital later this year and open the hospital as early as in the second half of next year. "Since the level of anti-infertility services in Taiwan is high and patients prefer local Taiwanese doctors, we plan to hire local doctors to operate the hospital," a CHA Healthcare official said. Taiwan is ranked as one of the countries with the most advanced sterility treatment environments in Asia, including the successful completion of in vitro fertilization in April 1985, which took place six months earlier than Korea and the provision of egg cells was legalized.

The CHA Medical Group has hospitals and research centers in the US, Australia, and Japan, and is planning to combine them into assets and list the assets on the stock market in Singapore where both medical care and finance are developed. To this end, the CHA Medical Group is expanding fertility clinics which the group already invested in in Australia and is seeking additional investment opportunities in the US and Vietnam. The CHA Medical Group emphasizes that expanding the network of overseas hospitals can lead to a spike in drug sales as well as new drug development. Cell therapy products being developed by CHA Biotech can be distributed through hospitals only, so hospital networks are important in the development stage, too. "We can secure an advantageous position in new drug development when we obtain clinical knowledge on various races by expanding our network of overseas hospitals," emphasized an official of the CHA Medical Group